• 1
    Chong M-Y, Tan CH, Fujii S et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin. Neurosci. 2004; 58: 6167.
  • 2
    Inagaki A, Inada T, Fujii Y et al. Equivalent Dose of Psychotropics. Seiwa Shoten, Tokyo, 1999.
  • 3
    Inagaki A, Inada T, Fujii Y et al. Dose equivalence of psychotropic drugs. Part XV: dose equivalence of novel neuroleptics. Perospirone. Jpn J. Clin. Psychopharmacol. 2001; 4: 869870.
  • 4
    Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs, 11th edn. Hogrefe and Huber, Toronto, 2001.
  • 5
    Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J. Clin. Psychiatry 2001; 62: 153157.
  • 6
    Yoshimura R, Nakamura J, Shinkai K et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum. Psychopharmacol. 2005; 20: 243248.
  • 7
    Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J. Pharm. Tech. 1995; 11: 5559.
  • 8
    McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series: treatment of schizophrenia. J. Clin. Psychiatry 1999; 60 (Suppl.): 815818.
  • 9
    Biancosino B, Barbui C, Marmai L, Dona S, Grassi L. Determination of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int. Clin. Psychopharmacol. 2005; 20: 305309.